Conferences - Results from #200

Viewing 201-220 of 11775 articles

ESMO 2024: First Results from ZZFIRST: a Randomized Phase II Trial of Enzalutamide with or without Talazoparib in Metastatic Hormone-naïve Prostate Cancer

ESMO 2024: Xaluritamig, a STEAP1 x CD3 XmAb 2+1 Immune Therapy, in Patients With Metastatic Castration-Resistant Prostate Cancer: Initial Results From Dose Expansion Cohorts in a Phase 1 Study

ESMO 2024: Symptomatic Skeletal Events, Health-Related Quality of Life and Pain in a Phase 3 Study of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer: Third Interim Analysis of PSMAfore

ESMO 2024: PSMA PET as a Game Changer for Decision Making?

ESMO 2024: Study EV-103 Dose Escalation/Cohort A: 5y Follow-Up Of First-Line Enfortumab Vedotin + Pembrolizumab in Cisplatin-Ineligible Locally Advanced Or Metastatic Urothelial Carcinoma

ESMO 2024: Subcutaneous Nivolumab vs Intravenous Nivolumab in Patients with Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma: Updated Efficacy and Safety Results from CheckMate 67T

ESMO 2024: Efficacy of Talazoparib and Enzalutamide in mCRPC Patients Previously Treated with Androgen Receptor Pathway Inhibitors or Docetaxel – Post Hoc Analysis from Both Cohorts in TALAPRO-2 Study

ESMO 2024: Updated Efficacy Profile of the Double Antibody Drug Conjugate (DAD) Phase I Trial: Sacituzumab Govitecan plus Enfortumab Vedotin in ≥ Second Line in Metastatic Urothelial Carcinoma (mUC)

ESMO 2024: Phase II Randomized Double-Blind Trial of Axitinib +/- PF 04518600, an OX40 Antibody after PD1/PDL1 Antibody Therapy in Metastatic Renal Cell Carcinoma – Final Analysis

ESMO 2024: Results from the Quick Efficacy Seeking Trial (QuEST1) Arm Combining BN-Brachyury (BNVax) + Bintrafusp Alfa + Nogapendekin Alfa Inbakicept-Pmln (N-803) in Castration-Resistant Prostate Cancer

ESMO 2024: Factors Influencing Clinical and Biological Response in Patients Treated with [177Lu]Lu-PSMA-617 Under France's Early Access Program

ESMO 2024: PSMA-targeted Radioligand Therapy with 131I-LNTH-1095 Plus Enzalutamide versus Enzalutamide Alone in Chemotherapy-naïve Patients Whose Piflufolastat F 18-avid Metastatic Castration-resistant Prostate Cancer Progressed on Abiraterone: ARROW

ESMO 2024: Prospective Evaluation of BCG Unresponsive Bladder Cancer CIS Identifies Genetic Mechanisms of Immunotherapy Resistance and Targeted Therapy using an Ultra-Sensitive Next Generation Sequencing Minimal Residual Disease Assay

ESMO 2024: Total and Regional Changes in Body Composition in Metastatic Hormone-Sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide +/- Zoledronic Acid. the BonEnza Study

ESMO 2024: Association of the Lipid Biomarker, PCPro, and Clinical Outcomes in the ENZAMET Trial (ANZUP 1304)

ESMO 2024: Final Safety and Efficacy Analysis of RaLu: 177Lu-PSMA Therapy in Patients with Prior Radium‑223

ESMO 2024: Real World Efficacy of 1st Line Nivolumab plus Ipilimumab and Its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13)

ESMO 2024: How to Manage Patients with Durable Response on Systemic Therapy? Optimal Therapy Duration and Role De-Escalation?

ESMO 2024: Prostate Cancer Working Group 4 Preliminary Criteria Using Serial PSMA PET/CT for Response Evaluation: Analysis from the PRINCE Trial

ESMO 2024: CaboPoint: Final Results from a Phase 2 Study of Cabozantinib After Checkpoint Inhibitor Combinations in Patients with Advanced Renal Cell Carcinoma

6
7
8
9
10
11
12
13
14
15